Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadazolid vs Vancomycin in Pediatric C. difficile Infection
NCT03105479Phase 3Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands, RNA-Targeting Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, single-blind trial of cadazolid in Clostridioides difficile infection (CDI) (7 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Clinical Cure Rate During Part B at Day 12, Maximal Plasma Concentration (Cmax) of Cadazolid During Part A at Day 10 and 3 more. Started Apr 2017; status: terminated.
02
Drugs
cadazolid
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03105479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105479.